Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats

Acta Pharmacologica Sinica

Volumn 32, Issue 2, 2011, Pages 217-222

  Li, Xue Qin ^a,b   Wang, Han Ming ^a   Yang, Chun Guang ^a   Zhang, Xin Hua ^a   Han, Dan Dan ^a   Wang, Huai Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Zhongshan City People's Hospital Guangdong Province   (China)

Author keywords

extracellular matrix; inflammation; pulmonary arterial hypertension; selective serotonin reuptake inhibitor

Indexed keywords

COLLAGEN; ELASTIN; FLUOXETINE; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MONOCROTALINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTERY MUSCLE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; LUNG HEMODYNAMICS; LUNG PARENCHYMA; MALE; NONHUMAN; PNEUMONIA; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; WESTERN BLOTTING;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FLUOXETINE; HYPERTENSION, PULMONARY; INFLAMMATION; LUNG; MALE; MATRIX METALLOPROTEINASES; MONOCROTALINE; PULMONARY ARTERY; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 79551672624     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.187     Document Type: Article

References (37)

1. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S20-31.
2. Tuder RM. Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30: 376-85.
3. Raiesdana A, Loscalzo J. Pulmonary arterial hypertension. Ann Med 2006; 38: 95-110.
4. Eble JA, Niland S. The extracellular matrix of blood vessels. Curr Pharm Des 2009; 15: 1385-400.
5. Lammers SR, Kao PH, Qi HJ, Hunter K, Lanning C, Albietz J, et al. Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves. Am J Physiol Heart Circ Physiol 2008; 295: H1451-9.
6. Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, et al. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001; 18: 838-45.
7. Ambalavanan N, Nicola T, Li P, Bulger A, Murphy-Ullrich J, Oparil S, et al. Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions. Pediatr Res 2008; 63: 26-32.
8. Novotná J, Herget J. Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia. Physiol Res 2002; 51: 323-34.
9. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, et al. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 2005; 25: 834-42.
10. Aytekin M, Comhair SA, de la Motte C, Bandyopadhyay SK, Farver CF, Hascall VC, et al. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295: L789-99.
11. MacLean MR, Dempsie Y. Serotonin and pulmonary hypertension - from bench to bedside? Curr Opin Pharmacol 2009; 9: 281-6.
12. MacLean MR, Dempsie Y. The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol 2010; 661: 309-22.
13. Kéreveur A, Callebert J, Humbert M, Hervé P, Simonneau G, Launay JM, et al. High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 2000; 20: 2233-9.
14. Song D, Wang HL, Wang S, Zhang XH. 5-Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells are extracellular signal-regulated kinase pathway dependent. Acta Pharmacol Sin 2005; 26: 563-7.
15. Li XQ, Hong Y, Wang Y, Zhang XH, Wang HL. Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol 2006; 33: 1047-51.
16. Zhai FG, Zhang XH, Wang HL. Fluoxetine protects against monocrotaline- induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats. Clin Exp Pharmacol Physiol 2009; 36: 850-6.
17. Dorfmüller P, Perros F, Balabanian K, Humber M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-63.
18. Mathew R. Inflammation and pulmonary hypertension. Cardiol Rev 2010; 18: 67-72.
19. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136: 678-87.
20. Hassoun PM, Mouthon L, Barberà JA, Eddahibi S, Flores SC, Grimminger F, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10-9.
21. Wang HL. The serotonin receptor and transporter are potential therapeutic targets for pulmonary hypertension. Curr Opin Investig Drugs 2004; 5: 963-6.
22. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog Neruopsychopharmacol Biol Psychiatry 2006; 30: 899-905.
23. Abdel-Salam OM, Baiuomy AR, Arbid MS. Studies on the anti-inflammatory effect of fluoxetine in rat. Pharmacol Res 2004; 49: 119-31.
24. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, et al. Serotonin transporter inhibition prevents and reversers monocrotaline- induced pulmonary hypertension in rats. Circulation 2005; 111: 2812-9.
25. Wang XM, Zhou TF, Liu B, Wei L, Shi K, Zhao SS, et al. Changes of MMP-2,9 and TIMP-1 expressions in rats with pulmonary arterial hypertension after captopril and losartan interventions. Sichuan Da Xue Xue Bao Yi Xue Ban 2009; 40: 255-9.
26. Tozzi CA, Thakker-Varia S, Yu SY, Bannett RF, Peng BW, Poiani GJ, et al. Mast cell collagenase correlateds with regression of pulmonary vascular remodeling in the rat. Am J Respir Cell Mol Biol 1998; 18: 497-510.
27. Emonard H, Grimoud JA. Matrix metalloproteinases. Cell Mol Biol 1990; 36: 131-53.
28. Fabre A, Marchal-Sommé J, Marchand-Adam S, Quesnel C, Borie R, Dehoux M, et al. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J 2008; 32: 426-36.
29. Passaretti TV, Wilcox BD, Jeffrey JJ. Serotonin regulation of gene expression in uterine extracellular matrix: reciprocal effects on collagens and collagenase. Mol Cell Endocrinol 1996; 120: 125-32.
30. Shum JK, Melendez JA, Jeffrey JJ. Serotonin-induced MMP-13 production is mediated via phospholipase C, protein kinase C, and ERK1/2 in rat uterine smooth muscle cells. J Biol Chem 2002; 277: 42830-40.
31. Benekareddy M, Mehrotra P, Kulkarni VA, Ramakrishnan P, Dias BG, Vaidya VA. Antidepressant treatments regulate matrix metalloproteinases- 2 and -9 (MMP-2/MMP-9) and tissue inhibitors of the metalloproteinases (TIMPS 1-4) in the adult rat hippocampus. Synapse 2008; 62: 590-600.
32. Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. Exp Eye Res 2009; 88: 676-82.
33. Kushnir-Sukhov NM, Gilfillan AM, Coleman JW, Brown JM, Bruening S, Toth M, et al. 5-hydroxytryptamine induces mast cell adhesion and migration. J Immunol 2006; 177: 6422-32.
34. Mikulski Z, Zaslona Z, Cakarova L, Hartmann P, Wilhelm J, Tecott LH, et al. Serotonin activates murine alveolar macrophages through 5-HT2C receptors. Am J Physiol Lung Cell Mol Physiol 2010; 299: L272-80.
35. Lima C, Souza VM, Soares AL, Macedo MS, Tavares-de-Lima W, Vargaftig BB. Interference of methysergide, a specific 5-hydroxytryptamine receptor antagonist, with airway chronic allergic inflammation and remodeling in a murine model of asthma. Clin Exp Allergy 2007; 37: 723-34.
36. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Cell Dev Biol 2008; 19: 34-41.
37. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001; 21: 199-206.